Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting

Press/Media: Press / Media

PeriodNov 9 2020 → Nov 10 2020

Media coverage

6

Media coverage

  • TitleVigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
    Media name/outletBioSpace
    CountryUnited States
    Date11/10/20
    PersonsDevalingam Mahalingam
  • TitleVigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
    Media name/outletPR Newswire
    CountryUnited States
    Date11/9/20
    PersonsDevalingam Mahalingam
  • TitleVigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
    Media name/outletMorningstar.com
    CountryUnited States
    Date11/9/20
    PersonsDevalingam Mahalingam
  • TitleVigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
    Media name/outletYahoo! Finance
    CountryUnited States
    Date11/9/20
    PersonsDevalingam Mahalingam
  • TitleVigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
    Media name/outletTickerTech.com
    CountryUnited States
    Date11/9/20
    PersonsDevalingam Mahalingam
  • TitleVigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
    Media name/outletWFMZ-TV Online
    CountryUnited States
    Date11/9/20
    PersonsDevalingam Mahalingam